Articles tagged with Breast Cancer
A nationwide study confirms the benefit of estrogen-lowering drugs before surgery for breast cancer patients. The treatment increased the likelihood that women could undergo breast-conservation surgery instead of mastectomy. After 16-week aromatase inhibitor therapy, 82% of women had successful breast-conservation surgery.
Peregrine's PS-targeting antibody bavituximab reactivates the immune system to attack and destroy cancer cells, potentially working synergistically with multiple therapies. The company plans to initiate two new Phase II trials in refractory and front-line lung cancer patients by mid-year.
Researchers at Henry Ford Hospital found that exercise programs like ExCITE improve quality of life and reduce fatigue in breast and prostate cancer patients. The study, which followed patients for one year after treatment completion, also showed benefits in physical and psychological well-being.
Researchers found that minor adjustments to estrogen receptor alpha and p53 genes can lead to precancerous changes in breast tissue. Testing healthy women for these gene variations may help predict future breast cancer risk.
Researchers at Beth Israel Deaconess Medical Center have identified palladin as a critical regulator of cell motility and migration in breast cancer. By inhibiting these processes, palladin helps suppress breast cancer invasion and metastasis.
Researchers from Georgetown University Medical Center identify a potential new combination therapy to increase or 'rescue' sensitivity to fulvestrant in ER+ breast cancers. The study found that the cytokine IFNγ appears to increase IRF1 expression, leading to increased apoptosis of cancer cells.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
A new study found that the number of circulating tumor cells in a patient's blood directly correlates with their survival time in metastatic breast cancer. The research suggests that monitoring these cells could improve personalized therapy for patients.
A powerful new technique for analyzing tumor cells has been developed, allowing scientists to study the biology of how tumors develop. An international team discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to anti-HER therapies.
A recent study presented at the ARRS Annual Meeting found that whole body MRI is highly accurate in detecting breast cancer metastases. The test identified bone metastases in 47 out of 99 patients with known breast cancer, while a chest X-ray only detected them in 24 patients.
Carla Finkielstein, a Virginia Tech Assistant Professor, has received the Minority Scholar Award in Cancer Research from the American Association for Cancer Research. The award recognizes her contributions to advancing cancer research and increasing diversity in the field.
Researchers developed a simple genetic test using three genes to classify breast cancer into sub-types, highlighting the importance of molecular classification in treatment outcomes. The study's findings suggest that these models are robust and can aid clinicians in making therapeutic decisions.
Research finds that estrogen receptor status in HER2+ breast cancer is correlated with response to anti-HER therapies. Patients with ER+/HER2+ cancers may benefit more from PI3K/AKT inhibitors, while ER-/HER2+ patients may see worse outcomes with hormonal therapy alone.
A study found that sulforaphane from broccoli limits breast cancer stem cells in mice and cell cultures, preventing tumor growth. Researchers believe eliminating these cells is key to controlling cancer, suggesting a potential new treatment approach.
A new study suggests that indeterminate breast lesions found in high-risk patients should be evaluated more aggressively to exclude a possible malignancy. The research found that 22% of these lesions were proven positive for cancer on follow-up and subsequent biopsy, highlighting the need for earlier evaluation.
The Fred Hutchinson Cancer Center has been awarded $10.24 million from the NIH to investigate breast cancer disparities among Hispanic women. The research aims to understand and prevent breast cancer in this population, with a focus on improving mammography screening rates and exploring the interplay of risk factors and biology.
A new study published in the Journal of the American College of Surgeons found that more than 90% of breast cancer patients had their expectations met or exceeded with regard to dates of service. The study highlights the importance of balancing timeliness with safety, effectiveness and equity in patient satisfaction.
A study suggests that breast magnetic resonance imaging (MRI) can detect breast lesions missed on mammography and ultrasound, influencing surgical management choices. Breast MRI positively impacts patient management decisions, potentially reducing the need for re-intervention by accurately assessing tumor extent.
Researchers found that tumor-secreted exosomes increase myeloid-derived suppressor cells, inhibiting immune activation and accelerating tumor metastasis. The study identified the role of MyD88 in this process, suggesting potential strategies to develop immune-stimulating tumor vaccines.
Dr. William Muller's research reveals how a particular gene regulates epithelial cells, leading to the loss of polarity and contributing to breast tumor formation. Reintroducing the gene into tumors shows promise in restoring polarity, suggesting new avenues for cancer treatment.
A review of available breast cancer risk assessment tools reveals their limitations, particularly in assessing individual risks. The models rely heavily on known risk factors, with up to 60% of breast cancers arising without them.
A new method has been developed to predict which women with DCIS are at high risk of developing more invasive tumors. The study found that two factors - the method of detection and biomarker expression - can identify patients who are most likely to develop invasive cancer within eight years.
A new study found that breast cancer risk factors differ significantly among Hispanic and non-Hispanic white women. In Hispanic women, known breast cancer risk factors were associated with only 7-36% of cases, compared to 62-75% in non-Hispanic whites.
A new study reveals that even slight reductions in PTEN expression can significantly increase cancer susceptibility in specific tissues, implying that environmental factors like diet and carcinogens may drive tumor development. This finding has implications for the development of diagnostic tests targeted to these gene alterations.
Molecular biologist Alan Ashworth will receive a $50,000 grant from the Samuel Waxman Cancer Research Foundation to study PARP inhibitors in BRCA-mutated cancers. His research aims to develop novel treatments for triple-negative breast cancer and other related cancers.
A recent study by the Oregon Health & Science University Knight Cancer Institute found that up to 49% of physicians interpreting screening mammograms could benefit from additional training. The study identified criteria for low-performance measures, targeting ranges of accuracy and potential overuse of tests.
A recent review found that approximately 25% of breast cancers and 60% of prostate cancers detected by screening tests may not be destined to cause symptoms or death due to overdiagnosis. This phenomenon leads to unnecessary treatment and other harms, emphasizing the need for strategies to address it.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
Researchers from Georgetown University Medical Center are studying multiple ways to address treatment-resistant breast cancers. A third approach involves triggering vulnerable cells to respond to existing treatments, while another study focuses on targeting orphan nuclear receptors to prevent resistance.
A new WHI analysis found an association between breast density changes and increased breast cancer risk in women taking estrogen plus progestin therapy. Researchers used mammograms from over 150,000 women, including those with invasive breast cancer, to determine that a decline in mammographic density was linked to lower cancer risk.
Researchers found that women with a breast density of 75% or higher have a four-to-five-fold increased risk of breast cancer. Decreases in breast density over time may be associated with lower breast cancer risk.
Researchers found a 28% reduced risk of developing breast cancer in women whose breasts decreased in density over time. The study suggests that measures of breast density may provide additional information for assessing breast cancer risk.
Researchers found elevated EGFR levels in blood of women with breast cancer 17 months prior to diagnosis, increasing risk by 2.9-fold. This marker shows promise as an early detection biomarker for breast cancer.
A prospective cohort study found that mid-life increase in body mass index (BMI) significantly increases the risk of postmenopausal breast cancer. Women who gained 5 kg/m2 or more between age 20 and study entry had a nearly twofold increased risk, with independent contributions from BMI gain before and after menopause.
Researchers at Fox Chase Cancer Center have identified NEDD9 as a key molecular player in the formation of HER2-driven breast tumors. The study shows that mice with the Nedd9 gene are more likely to develop tumors over an 18-month period, highlighting the protein's potential as a biomarker.
Researchers found that high levels of transforming growth factor beta 1 (TGF-β1) in breast cells may indicate atypical hyperplasia, a potentially precancerous condition. The study suggests that TGF-β1 could be part of a panel of genes and proteins used to identify women at risk of developing breast cancer.
Researchers at Georgetown Lombardi Comprehensive Cancer Center found that a high-fat diet during pregnancy increases breast cancer risk not only in daughters but also in their female and male offspring's daughters. The study suggests that pregnant mothers should eat well-balanced diets to potentially reduce the risk of breast cancer in...
Research reveals higher breast cancer rates among Latinas due to early diagnosis and poorer outcomes. Studies also show significant disparities in healthcare access and knowledge about screening practices among Mexican and Latina women living in the US.
Researchers found that vitamin supplements reduced breast cancer risk by about 30 percent, while calcium supplements reduced it by 40 percent. Calcium supplements lost their protective effect once DNA repair capacity was accounted for.
Researchers at Stanford University School of Medicine have identified a new genetic marker, called HOTAIR, that is significantly more prevalent in aggressive breast cancer cases. High levels of HOTAIR expression are associated with increased risk of metastasis and poorer survival rates for women with breast cancer.
Researchers at Washington University School of Medicine sequenced a patient's genome and that of her breast tumor and brain metastasis, identifying 20 genetic changes linked to the deadly spread. The study suggests that sequencing entire genomes can reveal clues to tumor progression and metastasis, paving the way for new drug targets.
Researchers discovered that larger body types at age seven were associated with a decreased risk of postmenopausal breast cancer. The study found that leaner girls had an increased risk of breast cancer, while larger bodies were protective against estrogen receptor negative tumours.
A new technique using tissue from below-the-waist 'love handles' improves cosmetic breast reconstruction in slim, athletic cancer patients. The method is less complicated than other options for surgeons and turns out to be effective in all 12 patients who underwent the procedure.
A study published in Pediatrics found that adolescent drinking increases the risk of benign breast disease, a precursor to breast cancer. The study, which followed over 6,900 girls aged 9-15, showed that girls who drank more frequently had higher rates of benign breast disease.
An international team of researchers has discovered a four-protein complex that promotes breast cancer metastasis. The complex, involving Myc, Skp2, Miz1, and p300, is a key regulator of RhoA gene expression. Targeting this complex could lead to the development of new drugs to thwart breast cancer migration and invasion.
A global study of nearly 10,000 women with early breast cancer found significant variations in treatment approaches across nine countries. Women with T1 tumours were more likely to receive breast-conserving surgery, while those with T2 tumours underwent mastectomies at varying rates.
Researchers discovered breast stem cells are exquisitely sensitive to oestrogen and progesterone, a finding that explains decades of evidence linking breast cancer risk to exposure to female hormones. The discovery also revealed the RANK ligand pathway is responsible for indirect control of breast stem cells in pregnancy.
Researchers discovered a peptide called iRGD that co-administers drugs to tumors, increasing treatment efficacy and reducing side effects. The peptide has been shown to enhance the therapeutic effect of anti-cancer drugs without creating new chemical entities.
Researchers at UC Davis Cancer Center found that African-American women with advanced breast cancer have poorer survival rates than white and Hispanic counterparts, regardless of radiation therapy. Despite lower radiation therapy rates, black patients did not benefit from the treatment.
A recent study published in the Journal of Clinical Oncology found that women with breast cancer before age 55 who carry an inherited mutation in BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite their initial tumor. The study revealed a higher risk of contralateral breast cancer among younger women wit...
Childhood cancer survivors may experience a 10-year reduction in life expectancy due to late effects of treatment, according to researchers. Furthermore, social connections play a significant role in shaping alcohol consumption rates, with individuals influenced by friends and acquaintances' drinking habits.
Researchers from the University of Gothenburg found that women with a known Western Swedish mutation in the BRCA1 gene have an increased risk of developing ovarian cancer. The study suggests that women without this mutation do not face an elevated risk, and provides clarity for targeted screenings.
A study published in Value in Health suggests that extending breast cancer screening to younger women could lead to better health programs and a more balanced approach to fighting the disease. The research found that screening only older women increases unfair disparities in life expectancy, quality of life, and disease incidence.
Research finds that occupational exposure to synthetic fibers and petroleum products before mid-30s may treble the risk of developing breast cancer after menopause. Women exposed to these chemicals have a seven-fold increased risk, with risks magnified by each additional decade of exposure.
Researchers at St. Jude Children's Research Hospital have identified a new class of compounds targeting the MDMX protein, implicated in promoting various cancers, including retinoblastoma. The compound, SJ-172550, has shown promise in killing cancer cells by binding to the protein and allowing p53 to function normally.
A new study from the University of Michigan found that mastectomy patients are less likely to receive radiation therapy than those who had lumpectomy. Despite medical guidelines recommending radiation after mastectomy for certain patients, only 78% received it, compared to 95% of lumpectomy patients.
A new study at the University of Illinois Chicago found that women who have given birth may be at increased risk for breast cancer due to inflammatory-related genes in their breast tissue. The researchers discovered a protective effect of pregnancy on breast cancer risk, suggesting a balance between high-risk inflammatory and protectiv...
Two new studies shed light on treatment options for women carrying BRCA1 and BRCA2 genetic mutations, which predispose them to breast cancer. Prophylactic mastectomy was found to have little impact on disease-free or overall survival, while breast conserving therapy with chemotherapy reduced recurrence rates in the breast.
The median survival time for metastatic breast cancer patients increased steadily over 25 years, with improved outcomes for those with grade III tumours. Targeted therapies, particularly trastuzumab, have contributed to these advancements, offering new hope for patients with aggressive forms of the disease.
The study found that PARP expression is present in all breast cancer subtypes and correlates with a total response to chemotherapy. Tumors with high PARP levels showed a significant improvement in overall survival.